Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2030

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Fulvestrant

Fulvestrant 500mg Days 0, 14, 28, then every 28 days

DRUG

Capecitabine Oral Product

Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off

Trial Locations (13)

510000

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Public Health Institute of Sun Yat-sen University, Guangzhou

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

Shantou Central Hospital, Shantou

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

NOT_YET_RECRUITING

Shenzhen People's Hospital, Shenzhen

RECRUITING

Affiliated Hospital of Guangdong Medical University, Zhangjiang

RECRUITING

Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai

RECRUITING

Affiliated Cancer Hospital of Guangxi Medical University, Nanning

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Herui Yao

OTHER